Unknown PHASE2 INTERVENTIONAL 1-arm NCT05166772

Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Efficacy and Safety of Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC） in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Sponsor: Tianjin Medical University Cancer Institute and Hospital

Conditions Hepatocellular Carcinoma

Interventions Donafenib HAIC Sintilimab

Updated 4 times since 2022 Last updated: Dec 21, 2021 Started: Dec 31, 2021 Primary completion: Dec 31, 2023 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hepatocellular Carcinoma, this trial is ongoing. The trial is conducted by Tianjin Medical University Cancer Institute and Hospital and has accumulated 4 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Jan 2025 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Jan 2022 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tianjin Medical University Cancer Institute and Hospital

Data source: Tianjin Medical University Cancer Institute and Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.